## Giovanni Passalacqua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4856145/publications.pdf Version: 2024-02-01

327	15,511	<sup>18436</sup> 62	23472
papers	citations	h-index	g-index
336 all docs	336 docs citations	336 times ranked	9023 citing authors

#	Article	IF	CITATIONS
1	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	1.5	1,199
2	Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Journal of Allergy and Clinical Immunology, 2010, 125, 569-574.e7.	1.5	406
3	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	1.6	395
4	Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. Journal of Allergy and Clinical Immunology, 2009, 123, 680-686.	1.5	360
5	A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organization Journal, 2013, 6, 17.	1.6	352
6	Subâ€lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	2.7	316
7	Long-lasting effects of sublingual immunotherapy according to its duration: AÂ15-year prospective study. Journal of Allergy and Clinical Immunology, 2010, 126, 969-975.	1.5	312
8	Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Annals of Allergy, Asthma and Immunology, 2006, 97, 141-148.	0.5	288
9	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	1.5	272
10	Noninjection routes for immunotherapy. Journal of Allergy and Clinical Immunology, 2003, 111, 437-448.	1.5	266
11	Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. Chest, 2008, 133, 599-609.	0.4	263
12	Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet, The, 1998, 351, 629-632.	6.3	252
13	Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2007, 119, 881-891.	1.5	251
14	lgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organization Journal, 2020, 13, 100080.	1.6	245
15	Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Annals of Allergy, Asthma and Immunology, 2008, 101, 206-211.	0.5	213
16	Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 2007, 120, 164-170.	1.5	210
17	Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Annals of Allergy, Asthma and Immunology, 2010, 105, 376-381.	0.5	180
18	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology, 2016, 170, 122-131.	0.9	164

#	Article	IF	CITATIONS
19	Diagnostic tools in Rhinology EAACI position paper. Clinical and Translational Allergy, 2011, 1, 2.	1.4	156
20	Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trialâ~†â~†â~†â~ Journal of Allergy and Clinical Immunology, 1999, 104, 964-968	1.5	155
21	The link between allergic rhinitis and asthma: the united airways disease. Expert Review of Clinical Immunology, 2010, 6, 413-423.	1.3	145
22	Grading local side effects of sublingual immunotherapy forÂrespiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	1.5	144
23	ARIA update: I—Systematic review of complementary and alternative medicine for rhinitis and asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1054-1062.	1.5	141
24	Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Annals of Allergy, Asthma and Immunology, 2010, 104, 215-222.	0.5	141
25	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	2.7	140
26	The nose–lung interaction in allergic rhinitis and asthma: united airways disease. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 7-13.	1.1	138
27	Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. Journal of Allergy and Clinical Immunology, 1995, 95, 612-621.	1.5	136
28	Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beingsâ țâ țâ țâ țâ Journal of Allergy and Clinical Immunology, 1997, 100, 122-129.	1.5	134
29	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
30	Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 776-781.	2.0	118
31	The Severe Asthma Network in Italy: Findings and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1462-1468.	2.0	112
32	Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Annals of Allergy, Asthma and Immunology, 2007, 98, 274-280.	0.5	107
33	United airways disease: therapeutic aspects. Thorax, 2000, 55, 26S-27.	2.7	106
34	Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptaseÂlevels. Journal of Allergy and Clinical Immunology, 2015, 136, 135-139.	1.5	102
35	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	1.6	100
36	Oral Immunotherapy for Egg Allergy: A Double-Blind Placebo-Controlled Study, with Postdesensitization Follow-Up. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 532-539.	2.0	98

#	Article	IF	CITATIONS
37	TIPS with Expanded Polytetrafluoroethylene–Covered Stent: Results of an Italian Multicenter Study. American Journal of Roentgenology, 2005, 185, 472-480.	1.0	97
38	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	1.4	97
39	NASAL cytology: practical aspects and clinical relevance. Clinical and Experimental Allergy, 2016, 46, 785-792.	1.4	97
40	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	1.5	95
41	Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone, 2011, 49, 880-885.	1.4	95
42	The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clinical Biochemistry, 2011, 44, 1005-1011.	0.8	91
43	COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 2020, 13, 100126.	1.6	90
44	Efficacy and safety of sublingual immunotherapy. Annals of Allergy, Asthma and Immunology, 2004, 93, 3-12.	0.5	87
45	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organization Journal, 2016, 9, 33.	1.6	87
46	Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 474-478.	2.0	85
47	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clinical Microbiology and Infection, 2020, 26, 1537-1544.	2.8	84
48	Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Annals of Allergy, Asthma and Immunology, 2009, 102, 22-28.	0.5	82
49	Nasal Eosinophils Display the Best Correlation with Symptoms, Pulmonary Function and Inflammation in Allergic Rhinitis. International Archives of Allergy and Immunology, 2005, 136, 266-272.	0.9	81
50	Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. Journal of Allergy and Clinical Immunology, 2005, 115, 1184-1188.	1.5	81
51	Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2008, 122, 44-48.	1.5	79
52	Birch-Apple Syndrome Treated with Birch Pollen Immunotherapy. International Archives of Allergy and Immunology, 2011, 156, 416-422.	0.9	79
53	Evidence of adherence to allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 544-548.	1.1	78
54	Quantitative assessment of the adherence to sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2004, 113, 1219-1220.	1.5	77

#	Article	IF	CITATIONS
55	Recommendations for appropriate sublingual immunotherapy clinical trials. Journal of Allergy and Clinical Immunology, 2009, 124, 665-670.	1.5	77
56	A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organization Journal, 2020, 13, 100091.	1.6	76
57	Ass's milk in children with atopic dermatitis and cow's milk allergy: Crossover comparison with goat's milk. Pediatric Allergy and Immunology, 2007, 18, 594-598.	1.1	73
58	Harmful effect of immunotherapy in children with combined snail and mite allergy. Journal of Allergy and Clinical Immunology, 2002, 109, 627-629.	1.5	71
59	Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Italian Journal of Pediatrics, 2017, 43, 13.	1.0	71
60	Allergen immunotherapy on the way to product-based evaluation—a WAO statement. World Allergy Organization Journal, 2015, 8, 29.	1.6	70
61	Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. Journal of Allergy and Clinical Immunology, 2008, 121, 256-257.	1.5	67
62	A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. Allergy and Asthma Proceedings, 2009, 30, 443-448.	1.0	65
63	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine, 2017, 4, 135.	1.2	65
64	Continuous Versus On Demand Treatment with Cetirizine for Allergic Rhinitis. Annals of Allergy, Asthma and Immunology, 1997, 79, 507-511.	0.5	62
65	Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Annals of Allergy, Asthma and Immunology, 2006, 97, 615-621.	0.5	62
66	The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1029-1033.	2.7	62
67	Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. International Immunology, 2009, 21, 779-791.	1.8	61
68	Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clinical and Experimental Allergy, 2013, 43, 22-28.	1.4	60
69	The IgE repertoire in children and adolescents resolved at component level: A crossâ€sectional study. Pediatric Allergy and Immunology, 2012, 23, 433-440.	1.1	59
70	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	1.1	59
71	Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy, Asthma and Clinical Immunology, 2016, 12, 2.	0.9	58
72	Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A novel SLIT formulation during a Year). Pediatric Allergy and Immunology, 2007, 18, 58-62.	1.1	57

#	Article	IF	CITATIONS
73	Asthma: personalized and precision medicine. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 51-58.	1.1	57
74	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	1.1	57
75	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	2.7	57
76	Pharmacokinetics of Der p 2 Allergen and Derived Monomeric Allergoid in Allergic Volunteers. International Archives of Allergy and Immunology, 2005, 138, 197-202.	0.9	56
77	Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatric Allergy and Immunology, 2013, 24, 376-381.	1.1	56
78	Large local reactions from stinging insects: from epidemiology to management. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 334-337.	1.1	53
79	Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Annals of Allergy, Asthma and Immunology, 2001, 87, 222-226.	0.5	51
80	Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). Journal of Allergy and Clinical Immunology, 2006, 117, 946-948.	1.5	51
81	Hypersensitivity to proton pump inhibitors: Diagnostic accuracy of skin tests compared to oral provocation test. Journal of Allergy and Clinical Immunology, 2012, 130, 547-549.	1.5	50
82	Role of contact sensitization in chronic urticaria. Journal of the American Academy of Dermatology, 2007, 56, 88-90.	0.6	49
83	Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1368-1372.	2.0	49
84	Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies. International Archives of Allergy and Immunology, 2003, 132, 1-12.	0.9	48
85	An update on the asthma-rhinitis link. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 177-183.	1.1	48
86	Adherence to sublingual immunotherapy in preschool children. Pediatric Allergy and Immunology, 2012, 23, 688-689.	1.1	48
87	Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. Pediatric Allergy and Immunology, 2011, 22, 803-807.	1.1	47
88	Effects of fexofenadine and other antihistamines on components of the allergic response. Journal of Allergy and Clinical Immunology, 2003, 112, S78-S82.	1.5	46
89	Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Annals of Allergy, Asthma and Immunology, 2010, 105, 223-227.	0.5	46
90	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46

#	Article	IF	CITATIONS
91	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. Journal of the American Academy of Dermatology, 2003, 49, 714-716.	0.6	44
92	Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due tograss pollen. Annals of Allergy, Asthma and Immunology, 2009, 102, 69-75.	0.5	44
93	Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1193-1195.	2.7	44
94	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respiratory Medicine, 2021, 176, 106261.	1.3	44
95	Allergen Immunotherapy. Immunology and Allergy Clinics of North America, 2016, 36, 1-12.	0.7	43
96	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: AÂGlobal Allergy and Asthma European Network (GA2LEN) article. Journal of Allergy and Clinical Immunology, 2011, 127, 49-56.e11.	1.5	42
97	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. BioMed Research International, 2018, 2018, 1-8.	0.9	42
98	Specific immunotherapy in asthma: efficacy and safety. Clinical and Experimental Allergy, 2011, 41, 1247-1255.	1.4	41
99	NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on shortâ€ŧerm ILâ€⊋ activation. European Journal of Immunology, 2013, 43, 550-561.	1.6	41
100	30 years of sublingual immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1107-1120.	2.7	41
101	Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects. British Journal of Sports Medicine, 2012, 46, 54-58.	3.1	40
102	Personalized Medicine in Allergy. Allergy, Asthma and Immunology Research, 2017, 9, 15.	1.1	40
103	Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2010, 105, 382-386.	0.5	38
104	Specific immunotherapy: beyond the clinical scores. Annals of Allergy, Asthma and Immunology, 2011, 107, 401-406.	0.5	38
105	Therapeutic interventions in severe asthma. World Allergy Organization Journal, 2016, 9, 40.	1.6	38
106	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	2.7	38
107	ALLERGY Net: The safety of sublingual immunotherapy with one or more allergens in adults. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 375-376.	2.7	37
108	The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 962-965.	2.7	37

#	Article	IF	CITATIONS
109	Sublingual grass and ragweed immunotherapy: Clinical considerations—a PRACTALL consensus report. Journal of Allergy and Clinical Immunology, 2016, 137, 369-376.	1.5	37
110	Intimate behavior and allergy: a narrative review. Annals of Allergy, Asthma and Immunology, 2007, 99, 394-400.	0.5	36
111	Local Side Effects of Sublingual and Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 13-21.	2.0	36
112	The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. World Allergy Organization Journal, 2018, 11, 34.	1.6	36
113	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Realâ€life observation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2539-2541.	2.7	36
114	Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Current Medical Research and Opinion, 2008, 24, 2829-2839.	0.9	33
115	Evidences of efficacy of allergen immunotherapy in atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 427-433.	1.1	33
116	Latex immunotherapy: state of the art. Annals of Allergy, Asthma and Immunology, 2012, 109, 160-165.	0.5	33
117	The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 20-24.	1.1	33
118	COVIDâ€19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	2.7	33
119	Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Annals of Allergy, Asthma and Immunology, 2001, 86, 433-438.	0.5	32
120	Allergenius, an expert system for the interpretation of allergen microarray results. World Allergy Organization Journal, 2014, 7, 15.	1.6	32
121	Nimesulide in the Treatment of Patients Intolerant of Aspirin and other NSAIDs. Drug Safety, 1996, 14, 94-103.	1.4	31
122	The Safety of Allergen Specific Sublingual Immunotherapy. Current Drug Safety, 2007, 2, 117-123.	0.3	31
123	The classification of allergic rhinitis and its cytological correlate. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1624-1625.	2.7	31
124	Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Annals of Allergy, Asthma and Immunology, 2013, 110, 51-54.	0.5	31
125	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAACIâ€GA <sup>2</sup> LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	2.7	31
126	A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis. Clinical Therapeutics, 2005, 27, 979-992.	1.1	30

#	Article	IF	CITATIONS
127	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	1.6	30
128	Comparison of the Effects in the Nose and Skin of a Single Dose of Desloratadine and Levocetirizine over 24 Hours. International Archives of Allergy and Immunology, 2004, 135, 143-147.	0.9	29
129	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. Current Allergy and Asthma Reports, 2016, 16, 88.	2.4	29
130	Sublingual immunotherapy: an update. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 31-36.	1.1	28
131	Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Preference and Adherence, 2010, 4, 141.	0.8	28
132	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	1.3	28
133	Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge. International Archives of Allergy and Immunology, 1998, 115, 157-161.	0.9	27
134	Are Physicians Aware of the Side Effects of Angiotensin-Converting Enzyme Inhibitors?. Chest, 2005, 128, 976-979.	0.4	27
135	When Allergic Rhinitis is not Only Allergic. American Journal of Rhinology and Allergy, 2009, 23, 312-315.	1.0	27
136	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Review of Respiratory Medicine, 2016, 10, 29-38.	1.0	27
137	Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. Clinical and Molecular Allergy, 2017, 15, 2.	0.8	27
138	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease, 2017, 11, 40-45.	1.0	27
139	Sublingual immunotherapy: update 2006. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 449-454.	1.1	26
140	Disease-modifying effect and economic implications ofÂsublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2011, 127, 44-45.	1.5	26
141	AIT (allergen immunotherapy): a model for the "precision medicine― Clinical and Molecular Allergy, 2015, 13, 24.	0.8	26
142	Underdiagnosis and Undertreatment of Asthma: A 9-Year Study of Italian Conscripts. International Archives of Allergy and Immunology, 2001, 125, 211-215.	0.9	25
143	Immunotherapy: clinical trials – optimal trial and clinical outcomes. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 561-566.	1.1	25
144	Systemic reactions to peach are associated with high levels of specific IgE to Pru p 3. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1795-1796.	2.7	25

#	Article	IF	CITATIONS
145	Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. Journal of Allergy and Clinical Immunology, 2003, 111, 1410-1412.	1.5	24
146	Factors that influence exhaled nitric oxide in Italian schoolchildren. Annals of Allergy, Asthma and Immunology, 2008, 101, 407-412.	0.5	24
147	Clinical and cytologic characteristics of allergic rhinitis in elderly patients. Annals of Allergy, Asthma and Immunology, 2012, 108, 141-144.	0.5	24
148	Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy, 2013, 5, 257-264.	1.0	24
149	Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 446-451.	1.1	24
150	ARIAâ€EAACI care pathways for allergen immunotherapy in respiratory allergy. Clinical and Translational Allergy, 2021, 11, e12014.	1.4	24
151	Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: Relationship with the atopic status. Pediatric Allergy and Immunology, 2003, 14, 458-463.	1.1	23
152	Local allergic rhinitis: entopy or spontaneous response?. World Allergy Organization Journal, 2016, 9, 39.	1.6	23
153	Oral immunotherapy for cow's milk allergy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 271-277.	1.1	22
154	Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations. Drug Safety, 2017, 40, 559-570.	1.4	22
155	Impact of Bariatric Surgery on Pulmonary Function and Nitric Oxide in Asthmatic and Non-Asthmatic Obese Patients. Journal of Asthma, 2011, 48, 553-557.	0.9	21
156	Specific immunotherapy in asthma: a comprehensive review. Journal of Asthma, 2014, 51, 29-33.	0.9	21
157	The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Research and Practice, 2015, 1, 4.	1.2	21
158	Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial. International Archives of Allergy and Immunology, 2017, 174, 97-103.	0.9	21
159	Local Nasal Specific Immunotherapy for Allergic Rhinitis. Allergy, Asthma and Clinical Immunology, 2006, 2, 117.	0.9	20
160	The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Annals of Allergy, Asthma and Immunology, 2011, 106, 407-411.	0.5	20
161	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	0.5	20
162	Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300Âindex of reactivity dose. Clinical and Translational Allergy, 2015, 5, 44.	1.4	20

#	Article	IF	CITATIONS
163	Molecular diagnosis and precision medicine in allergy management. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1705-1714.	1.4	20
164	Current insights in allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2018, 120, 152-154.	0.5	20
165	Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clinical and Experimental Allergy, 2005, 35, 880-883.	1.4	19
166	Vitamin D, allergies and asthma: focus on pediatric patients. World Allergy Organization Journal, 2014, 7, 27.	1.6	19
167	Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2Åpneumonia. Annals of Allergy, Asthma and Immunology, 2020, 125, 707-709.	0.5	19
168	Oral and sublingual immunotherapy in paediatric patients. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 139-145.	1.1	18
169	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. International Archives of Allergy and Immunology, 2008, 147, 231-234.	0.9	18
170	Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal, 2010, 3, 216-219.	1.6	18
171	Management of chronic rhinosinusitis. Pediatric Allergy and Immunology, 2012, 23, 32-44.	1.1	18
172	The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook. Expert Review of Clinical Immunology, 2015, 11, 141-154.	1.3	18
173	Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. Allergy, Asthma and Clinical Immunology, 2016, 12, 34.	0.9	18
174	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	1.6	18
175	Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. BioDrugs, 2001, 15, 509-519.	2.2	17
176	An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 375-380.	1.1	17
177	COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine, 2014, 9, 50.	0.6	17
178	The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. Clinical and Molecular Allergy, 2018, 16, 4.	0.8	17
179	Quick Olfactory Sniffin' Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients. World Allergy Organization Journal, 2021, 14, 100497.	1.6	17
180	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organization Journal, 2021, 14, 100592.	1.6	17

#	Article	IF	CITATIONS
181	Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. European Annals of Allergy and Clinical Immunology, 2006, 38, 31-4.	0.4	17
182	Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 173-177.	1.1	16
183	Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergologia Et Immunopathologia, 2006, 34, 82-83.	1.0	16
184	Adherence to sublingual immunotherapy: the allergists' viewpoint. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1796-1797.	2.7	16
185	Clinical effects of a Longâ€ŧerm Educational Program for Children with Asthma – Aironet <sup>®</sup> . A 1â€yr randomized controlled trial. Pediatric Allergy and Immunology, 2009, 20, 654-659.	1.1	16
186	The care pathway for children with urticaria, angioedema, mastocytosis. World Allergy Organization Journal, 2015, 8, 5.	1.6	16
187	Efficacy and safety of sublingual immunotherapy in children. Expert Review of Clinical Immunology, 2016, 12, 49-56.	1.3	16
188	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1460-1463.	2.7	16
189	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	2.7	16
190	Anaphylaxis due to patent blue dye during lymphography, with negative skin prick test. Journal of Investigational Allergology and Clinical Immunology, 2003, 13, 71-2.	0.6	16
191	Molecular events in allergic inflammation: experimental models and possible modulation. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 25-30.	2.7	15
192	Angioedema after administration of methylprednisolone to treat drug allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1346-1348.	2.7	15
193	Update on immunotherapy for the treatment of asthma. Current Opinion in Pulmonary Medicine, 2016, 22, 18-24.	1.2	15
194	Development of a nomogram to estimate the quality of life in asthmatic children using the Childhood Asthma Control Test. Pediatric Allergy and Immunology, 2016, 27, 514-520.	1.1	15
195	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 2019, 54, 87-89.	1.1	15
196	Biological agents for severe asthma: the evolution of the at-home self-injection approach. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 421-427.	1.1	15
197	Antihistamines in the Treatment of Bronchial Asthma. Present Knowledge and Future Perspectives. Pulmonary Pharmacology and Therapeutics, 2001, 14, 267-276.	1.1	14
198	Changing the route of immunotherapy administration: An 18-year survey in pediatric patients with allergic rhinitis and asthma. Allergy and Asthma Proceedings, 2013, 34, 523-526.	1.0	14

#	Article	IF	CITATIONS
199	The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clinical and Molecular Allergy, 2015, 13, 15.	0.8	14
200	Sublingual immunotherapy: focus on tablets. Annals of Allergy, Asthma and Immunology, 2015, 115, 4-9.	0.5	14
201	Allergen immunotherapy as add-on to biologic agents. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 502-508.	1.1	14
202	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 113-120.	1.5	14
203	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	1.6	14
204	Sensitization to Rabbit Allergens in Italy – A Multicentre Study in Atopic Subjects without Occupational Exposure. International Archives of Allergy and Immunology, 2006, 141, 295-299.	0.9	13
205	Long-term survival in elderly patients with a do-not-intubate order treated with noninvasive mechanical ventilation. International Journal of COPD, 2011, 6, 253.	0.9	13
206	Crossâ€sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. Pediatric Allergy and Immunology, 2014, 25, 473-480.	1.1	13
207	The safety of oral immunotherapy for food allergy during maintenance phase: Effect of counselling on adverse reactions. World Allergy Organization Journal, 2019, 12, 100010.	1.6	13
208	Single-Dose Oral Tolerance Test with Alternative Compounds for the Management of Adverse Reactions to Drugs. International Archives of Allergy and Immunology, 2002, 129, 242-247.	0.9	12
209	Clinical and therapeutic aspects of allergic asthma in adolescents. Pediatric Allergy and Immunology, 2003, 14, 453-457.	1.1	12
210	New perspectives in the treatment of allergic rhinitis and asthma in children. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 201-206.	1.1	12
211	Sublingual Immunotherapy: Other Indications. Immunology and Allergy Clinics of North America, 2011, 31, 279-287.	0.7	12
212	100 Years of Immunotherapy: The Monaco Charter. International Archives of Allergy and Immunology, 2013, 160, 346-349.	0.9	12
213	Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. Inflammation and Allergy: Drug Targets, 2006, 5, 43-51.	1.8	11
214	Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 966-967.	2.7	11
215	Sublingual immunotherapy: where do we stand? Present and future. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 1-3.	1.1	11
216	Sublingual Immunotherapy for Allergic Respiratory Diseases: Efficacy and Safety. Immunology and Allergy Clinics of North America, 2011, 31, 265-277.	0.7	11

#	Article	IF	CITATIONS
217	Immunotherapy in polysensitized patients: new chances for the allergists?. Annals of Allergy, Asthma and Immunology, 2012, 109, 392-394.	0.5	11
218	Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10. PLoS ONE, 2012, 7, e37980.	1.1	11
219	Advances in Allergen-Specific Immunotherapy. Current Drug Targets, 2009, 10, 1255-1262.	1.0	10
220	Evaluation and validation of a bee venom sting challenge performed by a micro-syringe. Annals of Allergy, Asthma and Immunology, 2012, 109, 438-441.	0.5	10
221	Allergen immunotherapy in asthma; what is new?. Asthma Research and Practice, 2015, 1, 6.	1.2	10
222	Clinical Characteristics Associated with Conjunctival Inflammation in Allergic Rhinoconjunctivitis. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 387-391.e1.	2.0	10
223	The path to personalized medicine in asthma. Expert Review of Respiratory Medicine, 2016, 10, 957-965.	1.0	10
224	Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years. Annals of Allergy, Asthma and Immunology, 2016, 116, 206-211.	0.5	10
225	Perioperative midazolam hypersensitivity in a sevenâ€yearâ€old boy. Pediatric Allergy and Immunology, 2017, 28, 400-401.	1.1	10
226	The role of the pharmacy in the management of bronchial asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 161-165.	0.5	10
227	Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology, 2003, 35, 393-6.	0.4	10
228	Safety and efficacy of immunotherapy with <i>Polistes dominulus</i> venom: results from a large Italian database. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1229-1230.	2.7	9
229	When sneezing indicates the cell type. International Forum of Allergy and Rhinology, 2013, 3, 393-398.	1.5	9
230	Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organization Journal, 2014, 7, 21.	1.6	9
231	Comparison of allergenic extracts from different origins: the value of the FDA's bioequivalent allergy unit (BAU). Expert Review of Clinical Immunology, 2016, 12, 733-739.	1.3	9
232	Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period. World Allergy Organization Journal, 2017, 10, 7.	1.6	9
233	Allergen-Specific Immunotherapy for Respiratory Allergy in Children: Unmet Needs and Future Goals. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 946-950.	2.0	9
234	The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 12-16.	1.1	9

#	Article	IF	CITATIONS
235	Tubercular tracheoesophageal fistulas in AIDS patients: primary repair and no surgery required?. Aids, 2007, 21, 2561-2564.	1.0	8
236	Serum cytotoxic T lymphocyte–associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 123, 258-260.	1.5	8
237	Allergy and the bone: unexpected relationships. Annals of Allergy, Asthma and Immunology, 2011, 107, 202-206.	0.5	8
238	The safety of monoclonal antibodies in asthma. Expert Opinion on Drug Safety, 2016, 15, 1087-1095.	1.0	8
239	Orphan immunotherapies for allergic diseases. Annals of Allergy, Asthma and Immunology, 2016, 116, 194-198.	0.5	8
240	Hymenoptera venom allergy in outdoor workers: Occupational exposure, clinical features and effects of allergen immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 477-483.	1.4	8
241	Evaluation of the safety of a protocol for switching venom immunotherapy products. Annals of Allergy, Asthma and Immunology, 2018, 120, 429-430.	0.5	8
242	A critical appraisal on AIT in childhood asthma. Clinical and Molecular Allergy, 2018, 16, 6.	0.8	8
243	Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 64-70.	1.1	8
244	Vitamin D levels and allergic diseases. An italian cross-sectional multicenter survey. European Annals of Allergy and Clinical Immunology, 2017, 49, 75-79.	0.4	8
245	Safety Profile of Sublingual Immunotherapy. Treatments in Respiratory Medicine, 2006, 5, 225-234.	1.4	7
246	New insights in sublingual immunotherapy. Current Allergy and Asthma Reports, 2006, 6, 407-412.	2.4	7
247	Novel therapeutic interventions for allergic rhinitis. Expert Opinion on Investigational Drugs, 2006, 15, 1615-1625.	1.9	7
248	Blowing a nose black and blue. Lancet, The, 2009, 373, 780.	6.3	7
249	Sublingual immunotherapy for allergic rhinitis: an update. Current Opinion in Otolaryngology and Head and Neck Surgery, 2011, 19, 43-47.	0.8	7
250	Novel <i>in silico</i> technology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management?. Expert Review of Clinical Immunology, 2014, 10, 1559-1561.	1.3	7
251	Potential of molecular based diagnostics and its impact on allergen immunotherapy. Asthma Research and Practice, 2016, 2, 9.	1.2	7
252	Umeclidinium for the treatment of uncontrolled asthma. Expert Opinion on Investigational Drugs, 2017, 26, 761-766.	1.9	7

#	Article	IF	CITATIONS
253	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from <i>in vitro</i> allergen-release data. Expert Review of Clinical Immunology, 2019, 15, 921-928.	1.3	7
254	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. Expert Review of Respiratory Medicine, 2020, 14, 163-172.	1.0	7
255	Medical devices in allergy practice. World Allergy Organization Journal, 2020, 13, 100466.	1.6	7
256	Allergen immunotherapy for pediatric asthma: current evidence and knowledge gaps. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 162-167.	1.1	7
257	Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic. World Allergy Organization Journal, 2021, 14, 100515.	1.6	7
258	Real-life studies in allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 361-367.	1.1	7
259	Specific Therapy for T2 Asthma. Journal of Personalized Medicine, 2022, 12, 593.	1.1	7
260	Safety of Allergen-Specific Sublingual Immunotherapy and Nasal Immunotherapy. , 2003, 82, 109-118.		6
261	Allergen Biodistribution in Humans. , 2003, 82, 33-43.		6
262	Emerging anti-inflammatory agents for allergic rhinitis. Expert Opinion on Emerging Drugs, 2005, 10, 689-705.	1.0	6
263	Specific immunotherapy among Italian specialists. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 898-899.	2.7	6
264	Investigational drugs for allergic rhinitis. Expert Opinion on Investigational Drugs, 2010, 19, 93-103.	1.9	6
265	Nasal inflammation in vernal keratoconjunctivitis. Journal of Allergy and Clinical Immunology, 2010, 125, 496-498.	1.5	6
266	Considerations about the evaluation of the SLIT meta-analyses. Journal of Allergy and Clinical Immunology, 2010, 125, 509.	1.5	6
267	Association of <i>Blattella germanica</i> sensitization with atopic diseases in pediatric allergic patients. Pediatric Allergy and Immunology, 2011, 22, 521-527.	1.1	6
268	Allergens and bacteria interaction in the induction of basophil activation. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 164-170.	1.1	6
269	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. Allergy and Asthma Proceedings, 2014, 35, 43-46.	1.0	6
270	Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis. Pediatric Allergy and Immunology, 2017, 28, 393-397.	1.1	6

#	Article	IF	CITATIONS
271	How to fit allergen immunotherapy in the elderly. Clinical and Molecular Allergy, 2017, 15, 17.	0.8	6
272	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. Human Vaccines and Immunotherapeutics, 2018, 14, 1438-1441.	1.4	6
273	Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region. World Allergy Organization Journal, 2019, 12, 100042.	1.6	6
274	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. Journal of Allergy and Clinical Immunology, 2019, 143, 1657-1658.	1.5	6
275	Severe asthma, biologicals, and autoâ€injection: Yes, no, may be!. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 444-445.	2.7	6
276	Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports. Respiratory Medicine Case Reports, 2020, 29, 100967.	0.2	6
277	Nonsteroidal Antiallergic Treatments in Allergic Rhinitis. American Journal of Rhinology & Allergy, 2000, 14, 319-324.	2.3	5
278	Euro coins and contact dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 669-670.	2.7	5
279	The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. Annals of Allergy, Asthma and Immunology, 2012, 108, 30-33.	0.5	5
280	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	2.4	5
281	Efficacy of Sublingual Immunotherapy. JAMA - Journal of the American Medical Association, 2013, 310, 643.	3.8	5
282	What lies beyond Asthma Control Test: Suggestions for clinical practice. Journal of Asthma, 2016, 53, 559-562.	0.9	5
283	Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. BioMed Research International, 2020, 2020, 1-4.	0.9	5
284	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	2.0	5
285	Seasonal sensorineural hearing loss associated with allergic rhinitis: A case report. Journal of Allergy and Clinical Immunology, 2006, 117, 468-469.	1.5	4
286	Anti-interleukin 5 therapies in severe asthma. Lancet Respiratory Medicine, the, 2017, 5, 537-538.	5.2	4
287	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy, 2020, 21, 1283-1286.	0.9	4
288	The perception of allergen-specific immunotherapy among Italian general practitioners. European Annals of Allergy and Clinical Immunology, 2014, 46, 83-6.	0.4	4

#	Article	IF	CITATIONS
289	The perception of allergen-specific immunotherapy among chest physicians: an Italian survey. European Annals of Allergy and Clinical Immunology, 2014, 46, 132-6.	0.4	4
290	Allergic and nonallergic rhinitis and skin sensitization to metals: is there a link?. European Annals of Allergy and Clinical Immunology, 2017, 49, 106-109.	0.4	4
291	The asthma-rhinitis association: Between the clinical hypothesis and the scientific theory. Current Allergy and Asthma Reports, 2003, 3, 191-193.	2.4	3
292	The relevance of house dust mites allergy in clinical practice: the epidemiological impact on allergen immunotherapy. Immunotherapy, 2017, 9, 1219-1224.	1.0	3
293	Personalizing the approach to asthma treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 299-304.	0.4	3
294	Latex-jujube cross-reactivity: case report and immunological study. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 971-972.	2.7	2
295	Emerging sublingual immunotherapy drugs. Expert Opinion on Pharmacotherapy, 2010, 11, 2963-2972.	0.9	2
296	Specific immunotherapy, one century later. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 551-553.	1.1	2
297	The Relevance of Nasal Cytology in the Workup of House Dust Mite-Induced Allergic Rhinitis. Allergy, Asthma and Immunology Research, 2018, 10, 283.	1.1	2
298	Asthma – Rhinitis Comorbidity. Allergy and Clinical Immunology International, 2003, 15, 105-109.	0.3	2
299	Noninjection Immunotherapy. Allergy and Clinical Immunology International, 2004, 16, 96-102.	0.3	2
300	Sublingual immunotherapy: what lessons can we draw from recent studies?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2004, 44, 584-589.	0.1	1
301	Complementary/alternative medicines in allergic disease. Expert Review of Clinical Immunology, 2005, 1, 113-121.	1.3	1
302	Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab. Expert Review of Clinical Immunology, 2007, 3, 463-467.	1.3	1
303	Immunotherapy – 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy. World Allergy Organization Journal, 2013, 6, P163.	1.6	1
304	Drug Hypersensitivity Reactions in Patients with Clonal Mast Cells Disorders. Journal of Allergy and Clinical Immunology, 2015, 135, AB122.	1.5	1
305	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy, 2016, 16, 1435-1441.	1.4	1
306	DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA. Chest, 2020, 158, A1752-A1754.	0.4	1

#	Article	IF	CITATIONS
307	An Update on Sublingual Immunotherapy. Allergy and Clinical Immunology International, 2005, 17, 181-185.	0.3	1
308	Antihistamines in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 1989, 44, 114-116.	2.7	1
309	Adverse Effects Associated with Sublingual Immunotherapy. , 2014, , 461-468.		1
310	Sublingual immunotherapy. Revista Alergia Mexico, 2003, 50, 220-5.	0.9	1
311	Does allergic rhinosinusitis exist?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 236-239.	0.1	Ο
312	Future and experimental therapeutic strategies for allergic rhinitis and asthma. Therapy: Open Access in Clinical Medicine, 2004, 1, 277-288.	0.2	0
313	Allergic Rhinitis in Women. Women's Health, 2007, 3, 603-611.	0.7	0
314	Reply to the letter by Dr de Bot. Pediatric Allergy and Immunology, 2007, 18, 628-628.	1.1	0
315	Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. World Allergy Organization Journal, 2008, 1, 70-72.	1.6	0
316	New approaches to the design of sublingual immunotherapy clinical trials. Clinical Investigation, 2011, 1, 805-814.	0.0	0
317	Emerging drugs for perennial allergic rhinitis. Expert Opinion on Emerging Drugs, 2012, 17, 543-553.	1.0	Ο
318	Evaluation and Validation of A Bee Venom Sting Challenge Performed by A MICRO-Syringe. Journal of Allergy and Clinical Immunology, 2013, 131, AB25.	1.5	0
319	Poster 1001: ALLERGENIUS®: an expert system for the interpretation of allergen microarrays. World Allergy Organization Journal, 2014, 7, P2.	1.6	0
320	Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. World Allergy Organization Journal, 2019, 12, 100086.	1.6	0
321	Legends of allergy and immunology: Ciorgio Walter Canonica—Physician, scientist, and visionary leader. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 695-697.	2.7	0
322	New Insights into Allergen-Specific Immunotherapy in Rhinitis and Asthma. , 2009, , 195-215.		0
323	Future and experimental therapeutic strategies for allergic rhinitis and asthma. Therapy: Open Access in Clinical Medicine, 2004, 1, 277-288.	0.2	0
324	Administration of sublingual vaccines. Clinical Allergy and Immunology, 2008, 21, 333-41.	0.7	0

#	Article	IF	CITATIONS
325	Adverse effects associated with sublingual immunotherapy. Clinical Allergy and Immunology, 2008, 21, 469-75.	0.7	0
326	Preventive effects of sublingual immunotherapy. Drugs of Today, 2008, 44 Suppl B, 83-6.	0.7	0
327	Obituary in memory of Giovanni Pajno. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2578-2579.	2.7	0